Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols

Arthritis Research and Therapy

Volumn 6, Issue 1, 2003, Pages

  Douni, Eleni ^a   Sfikakis, Petros P ^b   Haralambous, Sylva ^c   Fernandes, Peter ^d   Kollias, George ^a  

^a BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c HELLENIC PASTEUR INSTITUTE   (Greece)

^d Trans Bussan Chemedica International   (Switzerland)

Author keywords

arthritis; diacerein; inflammation; transgenic; tumor necrosis factor

Indexed keywords

EID: 9244246380     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1028     Document Type: Article

References (40)

1. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996, 14: 397-440. 10.1146/annurev.immunol.14.1.397. DOI: 10.1146/annurev.immunol.14.1.397
2. Sfikakis PP, Kollias G: Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol. 2003, 15: 380-386. 10.1097/00002281-200307000-00003. DOI: 10.1097/00002281-200307000-00003
3. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10: 4025-4031.
4. Probert L, Plows D, Kontogeorgos G, Kollias G: The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol. 1995, 25: 1794-1797. DOI: 10.1002/eji.1830250647
5. Yaron M, Shirazi I, Yaron I: Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage. 1999, 7: 272-280. 10.1053/joca.1998.0201. DOI: 10.1053/joca.1998.0201
6. Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J: Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage. 2000, 8: 186-196. 10.1053/joca.1999.0289. DOI: 10.1053/joca.1999.0289
7. Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J: Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol. 1998, 25: 2417-2424.
8. Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP: In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol. 1998, 25: 753-762.
9. Moore AR, Greenslade KJ, Alam CA, Willoughby DA: Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage. 1998, 6: 19-23. 10.1053/joca.1997.0088. DOI: 10.1053/joca.1997.0088
10. Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, Wigler I, Rosner IA, Beaulieu AD: Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000, 43: 2339-2348. 10.1002/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P. DOI: 10.1002/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P
11. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M: Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum. 2001, 44: 2539-2547. 10.1002/1529-0131(200111)44:11<2539::AID-ART434>3.0.CO;2-T. DOI: 10.1002/1529-0131(200111)44:11<2539::AID-ART434>3.0.CO;2-T
12. Lequesne M, Berdah L, Gerentes I: Efficacy and tolerance of diacerhein in the treatment of gonarthrosis and coxarthrosis [in French]. Rev Prat. 1998, Suppl: S31-S35.
13. Smith GN, Myers SL, Brandt KD, Mickler EA, Albrecht ME: Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum. 1999, 42: 545-554. 10.1002/1529-0131(199904)42:3<545::AID-ANR20>3.0.CO;2-4. DOI: 10.1002/1529-0131(199904)42:3<545::AID-ANR20>3.0.CO;2-4
14. Carney SL: Effect of diacetyl rhein on the development of experimental osteoarthritis. A biochemical investigation. Osteoarthritis Cartilage. 1996, 4: 251-261. DOI: 10.1016/S1063-4584(05)80103-7
15. Brandt KD, Smith G, Kang SY, Myers S, O'Connor B, Albrecht M: Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cartilage. 1997, 5: 438-449. DOI: 10.1016/S1063-4584(97)80048-9
16. Tamura T, Ohmori K, Nakamura K: Effect of diacerein on spontaneous polyarthritis in male New Zealand black/KN mice. Osteoarthritis Cartilage. 1999, 7: 533-538. 10.1053/joca.1999.0257. DOI: 10.1053/joca.1999.0257
17. Chan ES, Cronstein BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002, 4: 266-273. 10.1186/ar419. DOI: 10.1186/ar419
18. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH: Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001, 60: 729-735. 10.1136/ard.60.8.729. DOI: 10.1136/ard.60.8.729
19. Kirwan JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995, 333: 142-146. 10.1056/NEJM199507203330302. DOI: 10.1056/NEJM199507203330302
20. Jacobs JW, Geenen R, Evers AW, van Jaarsveld CH, Kraaimaat FW, Bijlsma JW: Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis. Ann Rheum Dis. 2001, 60: 61-64. 10.1136/ard.60.1.61. DOI: 10.1136/ard.60.1.61
21. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000, 343: 1586-1593. 10.1056/NEJM200011303432201. DOI: 10.1056/NEJM200011303432201
22. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056/NEJM200011303432202. DOI: 10.1056/NEJM200011303432202
23. Wooley PH: Collagen-induced arthritis in the mouse. Methods Enzymol. 1988, 162: 361-373. DOI: 10.1016/0076-6879(88)62091-X
24. Furst DE, Paulus HE: Aspirin and other non-steroidal anti-inflammatory drugs. In Arthritis and Allied Conditions. Edited by: McCarty D. 1993, Philadelphia: Lea & Febiger, 507-543. 12
25. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001, 345: 1098-1104. 10.1056/NEJMoa011110. DOI: 10.1056/NEJMoa011110
26. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003, 48: 319-324. 10.1002/art.10758. DOI: 10.1002/art.10758
27. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002, 46: 3151-3158. 10.1002/art.10679. DOI: 10.1002/art.10679
28. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN, Braun MM: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002, 46: 2565-2570. 10.1002/art.10583. DOI: 10.1002/art.10583
29. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G: Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002, 46: 785-792. 10.1002/art.10097. DOI: 10.1002/art.10097
30. Bessis N, Chiocchia G, Kollias G, Minty A, Fournier C, Fradelizi D, Boissier MC: Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin Exp Immunol. 1998, 111: 391-396. 10.1046/j.1365-2249.1998.00500.x. DOI: 10.1046/j.1365-2249.1998.00500.x
31. Schett G, Hayer S, Tohidast-Akrad M, Schmid BJ, Lang S, Turk B, Kainberger F, Haralambous S, Kollias G, Newby AC, Xu Q, Steiner G, Smolen J: Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis Rheum. 2001, 44: 2888-2898. 10.1002/1529-0131(200112)44:12<2888::AID-ART477>3.0.CO;2-3. DOI: 10.1002/1529-0131(200112)44:12<2888::AID-ART477>3.0.CO;2-3
32. Cruz TF, Tang J, Pronost S, Pujol JP: Molecular mechanisms implicated in the inhibition of collagenase expression by diacerheine [in French]. Rev Prat. 1996, 46: S15-S19.
33. Dozin B, Malpeli M, Camardella L, Cancedda R, Pietrangelo A: Response of young, aged and osteoarthritic human articular chondrocytes to inflammatory cytokines: molecular and cellular aspects. Matrix Biol. 2002, 21: 449-459. 10.1016/S0945-053X(02)00028-8. DOI: 10.1016/S0945-053X(02)00028-8
34. Tamura T, Kosaka N, Ishiwa J, Sato T, Nagase H, Ito A: Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthritis Cartilage. 2001, 9: 257-263. 10.1053/joca.2000.0383. DOI: 10.1053/joca.2000.0383
35. Felisaz N, Boumediene K, Ghayor C, Herrouin JF, Bogdanowicz P, Galerra P, Pujol JP: Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cartilage. 1999, 7: 255-264. 10.1053/joca.1998.0199. DOI: 10.1053/joca.1998.0199
36. Tamura T, Shirai T, Kosaka N, Ohmori K, Takafumi N: Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharmacol. 2002, 448: 81-87. 10.1016/S0014-2999(02)01898-8. DOI: 10.1016/S0014-2999(02)01898-8
37. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998, 102: 322-328. DOI: 10.1172/JCI2676
38. Kollias G, Douni E, Kassiotis G, Kontoyiannis D: On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev. 1999, 169: 175-194. DOI: 10.1111/j.1600-065X.1999.tb01315.x
39. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999, 10: 387-398. 10.1016/S1074-7613(00)80038-2. DOI: 10.1016/S1074-7613(00)80038-2
40. Wunder A, Muller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C: Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol. 2003, 170: 4793-4801. DOI: 10.4049/jimmunol.170.9.4793